The legal marijuana “green gold rush” has created many millionaires overnight…
Already dozens of tiny pot stocks are capitalizing on this explosion of wealth, and already we’ve seen real gains of 201%… 379%… 1,120%… 1,830%…
But all the fortunes that have been made so far are just the beginning.
Thanks to three recent developments, the legal marijuana industry is exploding again. It could double in the next 6 months alone.
So let's jump right in by sharing our up-to-date Marijuana Stock Hotlist:
Those gains look great, but fair warning…
Simply rushing out to buy the “hottest” and “latest” may be the kind of strategy that ruins your entire year.
Indeed, there’s one stock at the top of the list that has delivered life-changing gains…. but it's a wolf in sheep's clothing. Due to deceptive valuation and hype, it's arguably the worst place for any investor to put their money right now.
Here’s the point. Getting rich on speculation is all about timing and the right expert analysis.
That’s why you've got to see this ASAP…
The One Pot Stock to Buy Before Full Legalization
The FDA has already approved the first cannabis-based drug – Epidiolex – from GW Pharmaceuticals (on the hotlist above). Epidiolex can help eliminate epileptic seizures.
And its approval was a big reason GW's stock shot up 1,830%.
Now that's impressive. But Epidiolex is only approved to treat epilepsy – a $5 billion market.
The bigger the market for a cannabis treatment, the bigger the returns will be.
And 36 minutes into the American Cannabis Summit, former Speaker John Boehner just revealed an even better treatment with an even bigger market.
In fact, one tiny company (who only recently IPO'd) has released a treatment that's 10X more pure, even more powerful, and most importantly, is not limited to treating only epilepsy.
On top of also being able to take on the $5 billion seizure market, this new therapy could treat:
- Chronic pain ($77 billion opportunity)
- Sleep problems ($102 billion opportunity)
- Crohn's Disease ($7.6 billion opportunity)
That means while GW's drug is selling to a $5 billion market…
This firm's treatment is selling to a combined $191.6 billion market.
So we're talking about a company with 38X more potential!
And a company that can offer serious relief to millions upon millions more patients.
Go here to get the full story.
Right after John and Danny talk about this small medical firm, they discuss their favorite Cannabis Technology play, and a company building a billion-dollar brand.
These all have the potential for explosive growth and record profits for shareholders.
